CLINICAL_TRIALS
trial_result
· 2024-10-15
Clinical Trial Update: Atrasentan in Patients With IgA Nephropathy [Phase 3]
Summary
Phase 3 clinical trial update for atrasentan in IgA nephropathy; the study is currently active but not recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chinook Therapeutics, Inc. | Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING